This article was originally published Aug. 25.
Agilent Technologies said last week that the Broad Institute has used a new version of its SureSelect Human All Exon target enrichment kit to sequence the exomes of more than 5,100 human samples.
Agilent launched the SureSelect Human All Exon v2 kit, which covers 38 megabases of sequence and is more comprehensive than the first version, commercially last week. Like the original version, it developed the kit in collaboration with the Broad, which has used it for several months in its production pipeline.
So far, the Broad has used the v2 kit to sequence the exomes of more than 5,100 human samples "from a variety of cancer and heritable disease studies," said Sheila Fisher, assistant director of technology development for the Broad's genome sequencing center, in a statement.
In addition, Agilent offers the SureSelect Human All Exon 50 Mb kit, which it developed with the Wellcome Trust Sanger Institute as part of the Gencode project and which it released commercially earlier this month (IS 8/10/2010).